Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes - PACE-CME

Consistent CV benefit and tolerability of SGLTi in HF patients irrespective of diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

GLP-1RA treatment effect in patients with T2DM and PAD
GLP-1RA treatment effect in patients with T2DM and PAD
AHA 2019
GLP-1RA treatment effect in patients with T2DM and PAD
- Subodh Verma, MD, PhD
Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
AHA 2019
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
- Prof. Freek Verheugt, MD
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD